|
|
Characterization of a novel CD8+ T-cell subset with polyamine metabolism signature
Cimermanová, Veronika ; Štěpánek, Ondřej (advisor) ; Dobeš, Jan (referee)
CD8+ T cells play a crucial role in the adaptive immune response to combat infections and tumors. Previous research into T-cell heterogeneity has revealed that subsets of antigen- experienced CD8+ T cells possess different functional properties. However, the functional diversity might already be predetermined in their naïve steady-state precursors. Recently, the Lab of Adaptive Immunity discovered a new and rare murine steady-state CD8+ T-cell subset, known as Tpam cells (CD8+ T cells with polyamine metabolism signature). Since polyamine metabolism has been linked to T-cell activation and differentiation, studying this novel subset can provide new insight into the fate of CD8+ T cells upon TCR stimulation. This diploma thesis aimed to characterize Tpam cells in terms of their origin, steady-state phenotype, fate after TCR stimulation, and potential functional role. We took advantage of various mouse models to investigate the formation of Tpam cells and found that they are dependent on a diverse TCR repertoire and are presumably formed by low-grade TCR signaling. We executed an adoptive transfer into T-cell deficient mouse model to examine their steady-state phenotype and performed an ex vivo TCR-mediated activation assay to observe their fate after activation. Our findings show that Tpam cells are...
|
|
|
Surface expression of Tim-3 inhibitory molecule on antigen-specific CD8+ T cells expanded in vitro using dendritic cells for cell-based cancer immunotherapy
Svobodová, Hana ; Smrž, Daniel (advisor) ; Funda, David (referee)
Cancer is the second most common cause of death in the world, and the number of people with the disease increases each year. The therapy of the disease currently stands on four pillars; surgery, chemotherapy, radiotherapy, and immunotherapy. Through the past few years, immunotherapy has become the fastest developing treatment modality. However, despite its unprecedented efficacy in some patients, the majority of patients still does not respond to the therapy. Therefore, there is a need to investigate the mechanisms that make immunotherapy inefficient. Cell-based cancer immunotherapy is the treatment modality which uses live ex vivo-produced tumor-targeting immune cells to treat cancer. One of the mechanisms that may compromise its therapeutic efficacy is the expression of inhibitory molecules on the surface of the produced immune cells. Tim-3 is the inhibitory molecule which attracts attention in recent years. Tim-3 expression in the tumor cells and the tumor-infiltrating immune cells is often associated with worse prognosis and more aggressive forms of the disease. However, its role in the in vitro or ex vivo-produced immune cells is difficult to predict. In this work, an in vitro study model which is based on in vitro-produced antigen-specific CD8+ T cells with high expression of Tim-3 has been...
|
|
|
Immune response and tumor microenvironment in the treatment with polymer cytotoxic drugs
Malátová, Iva ; Šírová, Milada (advisor) ; Stollinová Šromová, Lucie (referee)
Chemotherapy is still one of the most widely used anticancer therapies. It is mostly about inhibiting the proliferation of rapidly dividing cells, so it is not selective for tumor cells. As a result, many undesirable side effects are associated with chemotherapy. The disadvantageous properties of chemotherapeutics can be largely eliminated by using conjugates of polymers with low molecular weight drugs. An example of such a conjugate is a doxorubicin-linked HPMA polymer. In addition to the properties obtained by polymer binding, such as achieving solubility in aqueous solutions, reducing systemic toxicity, increasing the maximum tolerated dose, or passive targeting by the EPR effect, the fact that doxorubicin induces immunogenic cell death is used in therapy with this drug. It has already been shown that after complete cure of the experimental mice with polymeric conjugates of HPMA with doxorubicin, some mice develop long-term resistance to re-inoculation with a lethal dose of tumor cells. Resistance is specific to the particular line of tumor cells from which the mouse was cured, and CD8+ cytotoxic T cells and IFNγ play an important role. In this work, we monitored changes in the proportion of immune populations and their activation markers after treatment with HPMA-based polymers with doxorubicin...
|
|
|
Surface expression of Tim-3 inhibitory molecule on antigen-specific CD8+ T cells expanded in vitro using dendritic cells for cell-based cancer immunotherapy
Svobodová, Hana ; Smrž, Daniel (advisor) ; Funda, David (referee)
Cancer is the second most common cause of death in the world, and the number of people with the disease increases each year. The therapy of the disease currently stands on four pillars; surgery, chemotherapy, radiotherapy, and immunotherapy. Through the past few years, immunotherapy has become the fastest developing treatment modality. However, despite its unprecedented efficacy in some patients, the majority of patients still does not respond to the therapy. Therefore, there is a need to investigate the mechanisms that make immunotherapy inefficient. Cell-based cancer immunotherapy is the treatment modality which uses live ex vivo-produced tumor-targeting immune cells to treat cancer. One of the mechanisms that may compromise its therapeutic efficacy is the expression of inhibitory molecules on the surface of the produced immune cells. Tim-3 is the inhibitory molecule which attracts attention in recent years. Tim-3 expression in the tumor cells and the tumor-infiltrating immune cells is often associated with worse prognosis and more aggressive forms of the disease. However, its role in the in vitro or ex vivo-produced immune cells is difficult to predict. In this work, an in vitro study model which is based on in vitro-produced antigen-specific CD8+ T cells with high expression of Tim-3 has been...
|
guest ::
